The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
23:51
Traian Băsescu criticizes Dacian Cioloș’s candidacy for the leadership of the Francophonie: “An immorality”
23:26
Jared Kushner Announces Progress in Negotiations to End the War in Ukraine
22:58
The Trump administration tightens rules on exporting U.S. chips to third countries to limit China’s access to AI technology
22:48
Zelenskyy asks European allies for missiles for Ukraine, following talks with US envoys about negotiations with Russia
22:38
Transgaz Director: The Mintia Power Plant Begins Commercial Production with the First Turbine, While the Second Enters Testing
See more news